Neoadjuvant Clinical Trials in Beijing, Beijing Municipality
9 recruitingBeijing, Beijing Municipality, China
Showing 1–9 of 9 trials
Recruiting
Phase 2
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Neoadjuvant TherapyLung NeoplasmsMinimal Residual Disease+1 more
Peking University People's Hospital100 enrolled1 locationNCT07291921
Recruiting
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
RadiotherapyLung Cancer (NSCLC)Neoadjuvant Immunotherapy+1 more
Peking University Cancer Hospital & Institute500 enrolled4 locationsNCT06926179
Recruiting
Not Applicable
Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
Breast CancerBreast MassesBreast Cancer Treated with Neoadjuvant Chemotherapy
Peking Union Medical College Hospital500 enrolled1 locationNCT06908291
Recruiting
Phase 2
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Cervical CancerNeoadjuvant ChemoimmunotherapyLocally Advanced Cervical Cancer+1 more
Tongji Hospital40 enrolled12 locationsNCT06288360
Recruiting
Phase 2
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
MelanomaAcral MelanomaNeoadjuvant+4 more
Peking University Cancer Hospital & Institute60 enrolled1 locationNCT05512481
Recruiting
Phase 2Phase 3
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Cervical CancerConcurrent ChemoradiotherapyNeoadjuvant Chemoimmunotherapy+1 more
Tongji Hospital440 enrolled12 locationsNCT06288373
Recruiting
Phase 3
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Neoadjuvant TherapyHead and Neck Squamous Cell CarcinomaPembrolizumab
Beijing Tongren Hospital272 enrolled1 locationNCT06102395
Recruiting
Not Applicable
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
Neoadjuvant TherapyMetastasisRectal Cancer+1 more
Beijing Chao Yang Hospital260 enrolled1 locationNCT04743102